- Manganese-Based Contrast Agents for Magnetic Resonance Imaging of Liver Tumors: Structure-Activity Relationships and Lead Candidate Evaluation
-
Gd-based MRI contrast agents (GBCAs) have come under intense regulatory scrutiny due to concerns of Gd retention and delayed toxicity. Three GBCAs comprising acyclic Gd chelates, the class of GBCA most prone to Gd release, are no longer marketed in Europe
- Wang, Junfeng,Wang, Huan,Ramsay, Ian A.,Erstad, Derek J.,Fuchs, Bryan C.,Tanabe, Kenneth K.,Caravan, Peter,Gale, Eric M.
-
p. 8811 - 8824
(2018/10/09)
-
- TRIAZOLO-PYRAZINE DERIVATIVES USEFUL IN THE TREATMENT OF DISORDERS OF THE CENTRAL NERVOUS SYSTEM
-
Provided herein are heteroaryl compounds, methods of their synthesis, pharmaceutical compositions comprising the compounds, and methods of their use. In one embodiment, the compounds provided herein are useful for the treatment, prevention, and/or management of various disorders, such as CNS disorders and metabolic disorders, including, but not limited to, e.g., neurological disorders, psychosis, schizophrenia, obesity, and diabetes.
- -
-
Paragraph 00257
(2014/06/23)
-
- NITROGEN-CONTAINING AROMATIC HETEROCYCLYL COMPOUND
-
The present invention provides a compound having excellent regulating action on blood lipid level. The present invention provides a compound represented by the following general formula (I) or a pharmacologically acceptable salt thereof, etc., wherein A represents a 5-membered nitrogen-containing aromatic heterocyclyl group; R1 represents COOH or the like; each R2 represents an alkyl or the like; each R3 represents an optionally substituted phenyl, an optionally substituted phenylalkyl, or the like; m represents 0, 1, 2, or 3; n represents 0 or 1; each of R4, R5, R6, and R7 represents H, an alkyl, or the like; and B represents an optionally substituted naphthyl, an optionally substituted aromatic heterocyclyl, or a group represented by the following formula (II) wherein each of B1 and B2 represents an optionally substituted phenyl or an optionally substituted aromatic heterocyclyl.
- -
-
Page/Page column 109
(2011/04/25)
-
- OXOTETRAHYDROFURAN-2-YL-BENZIMIDAZOLE DERIVATIVE
-
The present invention relates to compounds, which are useful for treatment and/or prevention of diabetes mellitus, diabetes mellitus complications or obesity, since the compounds have glucokinase-activating effects, and are presented in Formula (I): wherein R1 represents a carbamoyl group; R2 represents a lower alkyl group; both of X1 and X2 represent CH, or any one of X1 and X2 represents a nitrogen atom and the other represents CH; a group of represents a group selected from the group consisting of a pyridinyl, a pyrazinyl, a pyrazolyl, a thiadiazolyl, a triazolyl, an isoxazolyl and a thiazolyl group; and k is zero or 1, or relates to pharmaceutically acceptable salts thereof.
- -
-
Page/Page column 35
(2010/04/06)
-
- QUINOLINE DERIVATIVES
-
The invention concerns quinoline derivatives of Formula I or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
- -
-
Page/Page column 35
(2009/04/24)
-
- HETEROCYCLE-SUBSTITUTED BENZIMIDAZOLE DERIVATIVE
-
Compounds having glucokinase activating effects and being useful as treatments for diabetes, which are represented by the following formula (I): (wherein X1 to X4 represent a carbon atom, etc., ring A represents a 5- or 6-membered heteroaryl having from 1 to 4 hetero atoms selected from the group consisting of a nitrogen atom, a sulfur atom and an oxygen atom, X5 represent an oxygen atom, etc., X represent a carbon atom, etc., Het represents a 5- or 6-membered aliphatic hetero ring, R1 represents aryl, etc., R2 represents formyl, etc., R3 represents -C1-6 alkyl, etc.), as well as their pharmaceutically acceptable salts.
- -
-
Page/Page column 59
(2010/11/30)
-
- QUINAZOLINE DERIVATIVES
-
The invention concerns quinazoline derivatives of Formula (I) or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.
- -
-
Page/Page column 96
(2008/06/13)
-
- PYRAZOLE DERIVATIVE
-
A compound represented by Formula (I): wherein Ar1 represents Formula (II): Ar2 represents a 5- or 6-membered aromatic heterocyclic group which may be substituted; and X represents Formula (III): a salt thereof, or a solvate of the compound or the salt. A potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.
- -
-
Page/Page column 54-55
(2010/11/27)
-
- 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE
-
The present invention relates to a compound represented by Formula (I): wherein Ar1, Ar2, R1 and R2 each represent a substituent, a salt thereof, or a solvate of the compound or the salt, and to a medicine containing the same. According to the present invention, a potent platelet aggregation suppressant which does not inhibit COX-1 and COX-2 is provided.
- -
-
Page/Page column 24; 41
(2010/11/27)
-
- Pyridine-2-propanoic acids: Discovery of dual PPARα/γ agonists as antidiabetic agents
-
A series of novel pyridine-2-propanoic acids was synthesized. A structure-activity relationship study of these compounds led to the identification of potent dual PPARα/γ agonists with varied isoform selectivity. Based on the results of efficacy studies in
- Humphries, Paul S.,Almaden, Jonathon V.,Barnum, Sandra J.,Carlson, Thomas J.,Do, Quyen-Quyen T.,Fraser, James D.,Hess, Mary,Kim, Young H.,Ogilvie, Kathleen M.,Sun, Shaoxian
-
p. 6116 - 6119
(2008/12/20)
-
- First chiral synthesis of the N-terminal amino acid congener of nikkomycin Z based on lipase-catalyzed enantioselective acetylation of a primary alcohol possessing two stereogenic centers
-
A stereoselective synthesis of a versatile chiral synthon possessing two stereogenic centers, (2S,3S)-3-[2-(5-benzyloxypyridyl)]-2-methyl-1,3-propane diol 12 (>99% ee), was achieved by using a chemo-enzymatic method. The conversion of (2S,3S)-12 to the ho
- Akita, Hiroyuki,Takano, Yoshiki,Nedu, Katsushi,Kato, Keisuke
-
p. 1705 - 1714
(2007/10/03)
-
- A platform for designing HIV integrase inhibitors. Part 1: 2-Hydroxy-3-heteroaryl acrylic acid derivatives as novel HIV integrase inhibitor and modeling of hydrophilic and hydrophobic pharmacophores
-
We present a novel series of HIV integrase inhibitors, showing IC50s ranging from 0.01 to over 370 μM in an enzymatic assay. Furthermore, pharmacophore modeling study for the inhibitors was carried out to elucidate the structure-activity relationships. Finally, we found a 3D-pharmacophore model, which is composed of a hydrophilic and a hydrophobic domain, providing valuable information for designing other novel types of integrase inhibitors.
- Kawasuji, Takashi,Yoshinaga, Tomokazu,Sato, Akihiko,Yodo, Mitsuaki,Fujiwara, Tamio,Kiyama, Ryuichi
-
p. 8430 - 8445
(2008/02/05)
-
- FIVE-MEMBERED HETEROCYCLIC DERIVATIVE
-
The present invention relates to a compound represented by formula (I): a salt of the compound, or a solvate of the compound or the salt; a drug containing any of the compounds, the salts, and the solvates; a preventive and/or therapeutic agent for an ischemic disease containing any of the compounds, the salts, and the solvates; and a platelet coagulation inhibitor containing any of the compounds, the salts, and the solvates. The compound of the present invention is useful as a strong platelet coagulation inhibitor without inhibiting COX-1 or COX-2.
- -
-
Page/Page column 55
(2010/11/08)
-
- AMIDOPYRAZOLE DERIVATIVE
-
A platelet coagulation inhibitor which inhibits neither COX-1 nor COX-2 is provided. The inhibitor is a compound represented by general formula (I): wherein Ar1 and Ar2 independently represent a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents, or a phenyl group optionally substituted with 1 to 3 substituents; R1 represents a lower acyl group, carboxyl group, a lower alkoxycarbonyl group, a lower alkoxy group, a lower alkyl group optionally substituted with 1 or 2 substituents, a carbamoyl group optionally substituted with 1 or 2 substituents, an oxamoyl group optionally substituted with 1 or 2 substituents, an amino group optionally substituted with 1 or 2 substituents, a 4- to 7-membered alicyclic heterocyclic group optionally substituted with 1 or 2 substituents, a phenyl group optionally substituted with 1 to 3 substituents, or a 5- or 6-membered aromatic heterocyclic group optionally substituted with 1 to 3 substituents; and R2 represents hydrogen atom, a halogeno group, or the like.
- -
-
Page/Page column 31-32
(2010/11/23)
-
- SELECTIVE ESTROGEN RECEPTOR MODULATORS
-
The present invention provides a compound represented by the following formula (I); [wherein T represents a single bond, a C1-C4 alkylene group which may have a substituent and the like; formula (I-1) represents a single bond or a double bond; A represents a single bond, a bivalent 5- to 14-membered heterocyclic group which may have a substituent and the like; Y represents a single bond and the like; Z represents a methylene group and the like; ring G represents a phenylene group and the like which may condense with a 5- to 6-membered ring and may have a heteroatom; Ra and Rb are the same as or different from each other and represent a hydrogen atom and the like; W represents a single bond and the like; R' represents 1 to 4 independent hydrogen atoms and the like; and R" represents 1 to 4 independent hydrogen atoms and the like] or a salt thereof, or a hydrate thereof.
- -
-
Page/Page column 102
(2008/06/13)
-
- Alpha substituted carboxylic acids
-
Alpha substituted carboxylic acids of formula (I):
- -
-
-
- ALPHA SUBSTITUTED CARBOXYLIC ACID AS PPAR MODULATORS
-
Alpha substituted carboxylic acids of formula (I): wherein R' and R2 are as defined in the specification and R3 is A) formula (II); B) formula (III); C) formula (IV); and D) formula (V); wherein Y, Art, Are, AP, R4, R5, R6, R7, R6, R9, R9a, R10, R", R12, R17, ring A, and p are as defined in the specification; pharmaceutical compositions containing effective amounts of said compounds or their salts are useful for treating PPAR, specifically PPAR α/y related disorders, such as diabetes, dyslipidemia, obesity and inflammatory disorders.
- -
-
-
- INHIBITOR FOR ENZYME HAVING TWO DIVALENT METAL IONS AS ACTIVE CENTERS
-
A pharmaceutical composition for use as an inhibitor of an enzyme having two divalent metal ions as an active center was found. It is possible to inhibit the activity of an enzyme by a compound capable of chelating both of the two divalent metal ions.
- -
-
-
- Quinolizinones as integrin inhibitors
-
The present invention is directed towards novel compounds that are effective inhibitors of integrins, particularly αIIbβ3 or αv integrins such as αvβ3 and αvβ5. One embodiment of the present invention comprises a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt, solvate, or metabolic precursor thereof. R1, R2, R3, and R4 are defined herein.
- -
-
-
- New highly active taxoids from 9β-dihydrobaccatin-9,10-acetals. Part 4
-
It was shown that a new taxane analogue 3, which exhibited both in vitro antitumor activity and in vivo efficacy by both iv and po administration, was prone to be metabolized by human liver microsomes. We identified a major metabolite, M-1, generated by h
- Takeda, Yasuyuki,Uoto, Kouichi,Chiba, Jun,Horiuchi, Takao,Iwahana, Michio,Atsumi, Ryo,Ono, Chiho,Terasawa, Hirofumi,Soga, Tsunehiko
-
p. 4431 - 4447
(2007/10/03)
-
- INTEGRASE INHIBITORS CONTAINING AROMATIC HETEROCYCLE DERIVATIVES
-
A compound of the formula (I): whereinX is hydroxy or the like;Y is -C(=R2)-R3-R4 wherein R2 and R3 is oxygen atom or the like, R4 is hydrogen, optionally substituted alkyl, optionally subs
- -
-
-
- Substituted 2-acylpyridine-α-(N)-hetarlyhydrazones and medicaments containing the same
-
Substituted 2-acylpyridine-α-(N)-hetarylhydrazones are described, which are suitable as active substances for the treatment of antimicrobial and in particular antimycobacterial diseases, as well as active substances for the treatment of malaria or malignant tumours. The compounds have a marked synergistic activity combined with inhibitors of folate synthase, dihydrofolic acid reductase, DNA-synthesis and RNA-synthesis.
- -
-
-
- 2-Pyridinecarboxylic acids
-
5-Etherified 2-pyridinecarboxylic acids, e.g. those of the formula STR1 or functional derivatives thereof, are hypotensive agents.
- -
-
-
- 2-Pyridinecarbonitrile compounds
-
5-Etherified 2-pyridinecarboxylic acids, e.g. those of the formula STR1 R = phenyl or (alkyl, alkoxy, halogeno, CF3, CN, CONH2 or NH2)-phenyl R' = H or carboxy X = O or S, m = 1-4 or functional derivative thereof, are hypotensive agents.
- -
-
-